Reliable and trusted sites with CURRENT information, therapies and resources.

The Jack H. Marston II Melanoma Fund is devoted to advocacy and educational purposes only and does not replace or substitute professional medical care.  Information provided by Jack’s Fund should not be used for diagnosing or treating a skin problem or disease.  If you have or suspect you have a skin problem, please consult with a dermatologist, or other qualified professional healthcare provider.



Separate page dedicated to the importance of early detection and statistics surrounding the disease.





1) The Surgeon General’s Call to Action to Prevent Skin Cancer |

2)  call-to-action-prevent-skin-cancer

3) Letter of Commendation:  USSG to Jack’s Fund

VIDEO: Apr 2015, Huntsman Cancer Institute. Researchers say they are closing in on melanoma cureDr. Robert Andtbacka, one of Huntsman’s leading oncologists, said the revolutionary new treatment actually teaches the body to heal itself.

ARTICLE: Mar 2015, Cancer Research Institute.  What Cancer Patients Need to Know About the Opdivo Approval.  Now that Opdivo (nivolumab) has been FDA approved for two cancer types and potentially more in the coming months …

ARTICLE: Mar 2015, Cancer Research Institute.  Merck’s PD-1 Drug Outperforms Ipilimumab for Treatment of Advanced Melanoma.  The success of ipilimumab was about more than the triumph of an individual drug. It also validated a new and powerful approach to cancer immunotherapy.

ARTICLE: Mar 2015, Immuno-Oncology News. Four years ago, we had nothing to improve advanced melanoma patients’ survival, and now we have several new therapies available, with several others in the pipeline …

ARTICLE: Mar 2015: OncLive. PD-1 Pathway Combos Lead the Way in RCC Immunotherapy

ARTICLE: Feb 2015, OncLive. PD-1 Agents Vie for Frontline Spot in Melanoma Immunotherapy

PD-1 Agents Vie for Frontline Spot in Melanoma Immunotherapy – See more at:

ARTICLE: Jan 2015, National Cancer Institute: Precision Medicine Initiative and Cancer Research.  After decades of research, we are poised to enter a new era of medical practice where detailed genetic and other molecular information about a patient’s cancer is routinely used to deploy effective, patient-specific remedies to treat it. We are about to enter the era of precision medicine.

ARTICLE: Dec 2014, FDA Approves Nivolumab for Advanced Melanoma.  The FDA has approved the PD-1 inhibitor nivolumab (Opdivo) for patients with metastatic melanoma following treatment with ipilimumab or a BRAF inhibitor, based on data from the phase III CheckMate-037 trial.

ARTICLE:  Nov 2014, Next Gen-Melanoma Drug TAK-733, University of Colorado Cancer Center.  According to National Cancer Institute statistics, approximately 1 million people in the United States live with melanoma at any given time. 

ARTICLE: Oct 2014, New Immunotherapy Drugs: How they WorkTurning a patient’s own immune system against their cancer has long been considered the Holy Grail of cancer therapy.

UPDATE:  July 2014,  MD Anderson Melanoma Clinical Trials

PODCAST: July 2014, Wistar Institute.  Immunotherapies – Strengthening our own defenses to fight cancer

ARTICLE: June 2014 John Hopkins Medicine: More Arrows in the Arsenal Dramatic advances in immunotherapy offer new options for patients with advanced melanoma—and could even make chemotherapy a thing of the past.

VIDEO:  June 2014 ASCO Meeting: What is high-dose interleukin-2 Therapy?

ARTICLE:  June 2014: Global Post Immunotherapy Shows Promise against melanoma

ARTICLE: May 2014: Bloomberg: Immune Therapy’s Cancer Promise Creates Research Rush

ARTICLE: May 2014 – OncLive:  Vemurafenib Combination Effective in Advanced BRAF Mutant Melanoma.

ARTICLE: Apr 2014 – HemOncToday: Sun exposure, family history guide risk assessment for melanoma screening

ARTICLE: Apr 2014 – HemOncToday:  Ipilimumab may become standard of care for adjuvant melanoma therapy

ARTICLE:  Apr, 2014 – NATURE: Cancer treatment: The killer withinThe immune system can be a powerful weapon against cancer — but researchers are still grappling with how to control it.

ARTICLE:  Mar, 2014 – AAD: New Hope for Patients with advanced melanoma

ARTICLE: Mar, 2014 – OncLive:  Nivolumab Delivers Durable Remissions With Low Toxicity in Advanced Melanoma

ARTICLE: Feb 2014 – Med Xpress:  Drug Identified that could block the spread of melanoma.

ARTICLE:  Feb, 2014 – The Oncology Report: Immunotherapy for melanoma progresses with some interesting response patterns

ARTICLE:  Feb, 2014 – Washington Post:  Therapies raise hope for a breakthrough

ARTICLE: Feb, 2014 – National Cancer Institute:  Dana-Farber Researcher find that Marker may predict response to ipilimumab in advanced melanoma.  Read More

ARTICLE:  MD ANDERSON NEWSLETTER Jan, 2014:  Current Medical Trials in Melanoma Oncology – Page 1 / Page 2

ARTICLE:  May, 2013 from Early Research Suggests That Ipilimumab and Nivolumab Work Better Together for Advanced Melanoma READ MORE



Making a world of difference in cancer care MANAGING THE COST OF CANCER CARE BOOKLET
ASCOCancer on YouTube




OncLive is the official Website for the Oncology Specialty Group, which publishes Oncology & Biotech News, OncologyLive, Oncology Nursing News, and Urologists in Cancer Care.  The mission of OncLive and these publications is to provide oncology professionals with the resources and information they need to provide the best patient care.



Mission Statement: Conquering cancer worldwide by funding breakthrough cancer research and sharing cutting-edgeknowledge.

Vision: A world free from the fear of cancer.




Each person and each melanoma are different, and at MD Anderson’s Ben Love/El Paso Corporation Melanoma and Skin Center, we use our unique multidisciplinary approach to tailor melanoma treatment specifically to your unique situation. Our team of internationally recognized experts customizes your care to ensure you receive the most advanced treatments with the least impact on your body.

July 10, 2014 – Updated Clinical Trials in Melanoma Medical Oncology.






Information about melanoma treatment, prevention, causes, screening, clinical trials, research, and other topics from the National Cancer Institute.

 U.S. National Institutes of Health. is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world.


Fast Cures logo

FasterCures, a center of the Milken Institute, is an action tank, determined to remove barriers to medical progress.  We have only one goal: to save lives as rapidly as possible. We work to improve the medical research system – so that we can speed up the time it takes to get important new medicines from discovery to patients



Center Watch

Helping People Connect with Clinical Trials CenterWatch is the leading trusted source for global clinical trial information.




Uptodate logo

 UpToDate® is the premier evidence-based clinical decision support resource, trusted worldwide by healthcare practitioners to help them make the right decisions at the point of care. It is proven to change the way clinicians practice medicine, and is the only resource of its kind associated with improved outcomes.



Better medicine begins with knowledge.  Established in 1892 as the nation’s first independent medical research institution, The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. At the scientific forefront and with a record of success, Wistar strives to embody its slogan: Today’s Discoveries—Tomorrow’s Cures.




Front Line Medical News 



medical express

 Cancer News




CHOMS: Reducing the Impact of Cancer and Blood Disorders in the Chicago Community




NEJM is the most widely read, cited, and influential general medical periodical in the world. As it evolves to meet the changing needs of its readers in the 21st century, it is committed to maintaining that reputation and integrity, while using innovative formats and technologies for new features and faster delivery and access.



JAAD logo








oncology nurses logo




**Disclaimer: The Jack H. Marston II Melanoma Fund is devoted to advocacy and educational purposes only and does not replace or substitute professional medical care. Information provided by Jack’s Fund should not be used for diagnosing or treating a skin problem or disease. If you have or suspect you have a skin problem, please consult with a dermatologist, or other qualified professional healthcare provider.